Trial Profile

A Phase II, Open-Label Trial Using VELCADE for Re-Treatment of Multiple Myeloma Subjects Following an Initial Response to VELCADE

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 05 Oct 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bortezomib (Primary) ; Dexamethasone
Indications Multiple myeloma
Focus Registrational; Therapeutic Use
Acronyms RETRIEVE
Sponsors Janssen-Cilag

Most Recent Events

08 Aug 2014 Primary endpoint (Objective clinical response rate) has been met, according to a Takeda media release.
08 Aug 2014 Top-line results published in a Takeda media release.
08 Aug 2014 Based on the results of this trial, the US FDA has approved bortezomib for retreatment of adults with multiple myeloma who had previously responded to VELCADE therapy and relapsed, according to a Takeda media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com